Pharmos Corp. (PARS)
-OTC Markets 0.04 May 20, 2:04PM EDT|Pre-Market
:
NaN
| Prev Close: | 0.04 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 30-May-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.02 - 0.09 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 28,534 |
|---|
| Market Cap: | 2.22M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.03 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- PHARMOS CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Change in Directors or Principal OffiEDGAR Online(Wed, Jan 2)
- PHARMOS CORP FinancialsEDGAR Online Financials(Sat, Nov 24)
- PHARMOS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, Nov 19)
- PHARMOS CORP Files SEC form 8-K, Other EventsEDGAR Online(Wed, Nov 14)
- Pharmos Announces Levotofisopam for Gout Presented at ACR MeetingMarketwired(Mon, Nov 12)
- PHARMOS CORP Files SEC form 8-K, Other EventsEDGAR Online(Wed, Oct 17)
- PHARMOS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, Jul 30)
- PHARMOS CORP Files SEC form 8-K, Financial Statements and ExhibitsEDGAR Online(Fri, May 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Pharmos Corporation, a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat a range of metabolic and nervous system disorders.
View More